Sandoz + Fougera = 4 Topical Generics For Tolmar
This article was originally published in The Pink Sheet Daily
FTC’s proposed consent agreement requires the Novartis unit to return marketing rights to calcipotriene topical solution, lidocaine-prilocaine cream and metronidazole topical gel to Tolmar Inc., as well as rights to market a future generic version of Solaraze (diclofenac sodium gel).
You may also be interested in...
Sandoz is acquiring the U.S. generics dermatology business Fougera, which formerly belonged to Nycomed, for $1.5 billion in cash, giving it entry into a highly profitable niche market.
The nine drug manufacturers with products selected for Medicare drug price negotiations have agreed to participate in the program. Seven of them now have pending suits challenging the Inflation Reduction Act program with Novo’s recent complaint, which objects to the aggregation of its insulin products.
Drug manufacturers will have to participate in the Medicare drug price negotiation process for the foreseeable future. Judge Newman's finding that participation in Medicare is voluntary could defeat constitutional challenges to the program and have an impact on other cases.